Explore opportunities with Novartis below.
Rolling forward its mid-term guidance with strong 2024 performance as the base year, Novartis now expects to grow sales at +5% CAGR 2024-2029. The company remains on track to deliver core operating ...
Acquisition of Kate Therapeutics enhances and strengthens Novartis strategic priorities in gene therapy and neuroscience innovation Transaction includes enabling technology platforms and therapeutic ...
Basel, November 19, 2024 – Novartis has ranked first in the 2024 Access to Medicine Index (ATMI) report published today, highlighting the company’s leadership in improving access to medicines around ...
Why Novartis: Helping people with disease and their families takes more than innovative science. It takes a community of smart, passionate people like you. Collaborating, supporting and inspiring each ...
PatientInnenorganisationen und Selbsthilfegruppen leisten unschätzbaren Beitrag für Betroffene & Angehörige Novartis bat sie mit der Auslobung des 3. „Patient Innovation Awards“ (PIA) erneut auf den ...
Why Novartis: Helping people with disease and their families takes more than innovative science. It takes a community of smart, passionate people like you. Collaborating, supporting and inspiring each ...
Montreal, November 15, 2024 – Novartis Pharmaceuticals Canada Inc. (Novartis Canada) is extremely disappointed that negotiations for PLUVICTO™ (lutetium (177Lu) vipivotide tetraxetan injection), a ...
Why Novartis: Helping people with disease and their families takes more than innovative science. It takes a community of smart, passionate people like you. Collaborating, supporting and inspiring each ...
Why Novartis: Helping people with disease and their families takes more than innovative science. It takes a community of smart, passionate people like you. Collaborating, supporting and inspiring each ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback